Asfotase alfa
Asfotase Alfa (pronounced as-FO-tase AL-fa) is a medication used to treat a rare genetic disorder known as Hypophosphatasia (HPP).
Etymology
The name "Asfotase Alfa" is derived from the enzyme it replaces, "alkaline phosphatase," and "alfa," a common suffix in pharmaceutical naming indicating the first in a series or class.
Usage
Asfotase Alfa is used to treat patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). HPP is a rare, genetic, metabolic disease where there is a deficiency of the tissue-nonspecific alkaline phosphatase (TNSALP) enzyme, leading to a variety of systemic complications. Asfotase Alfa is a recombinant human TNSALP enzyme replacement therapy that aims to restore the enzyme activity in patients with HPP.
Dosage
The dosage of Asfotase Alfa varies depending on the patient's weight and the severity of the condition. It is administered via subcutaneous injection.
Side Effects
Common side effects of Asfotase Alfa include injection site reactions, lipodystrophy (abnormal fat distribution), ectopic calcifications, and allergic reactions.
Related Terms
- Hypophosphatasia
- Enzyme Replacement Therapy
- Alkaline Phosphatase
- Subcutaneous Injection
- Lipodystrophy
- Ectopic Calcifications
External links
- Medical encyclopedia article on Asfotase alfa
- Wikipedia's article - Asfotase alfa
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski